431 related articles for article (PubMed ID: 25364233)
1. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Wang YY; Yang YX; Zhe H; He ZX; Zhou SF
Drug Des Devel Ther; 2014; 8():2075-88. PubMed ID: 25364233
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids.
Borella R; Forti L; Gibellini L; De Gaetano A; De Biasi S; Nasi M; Cossarizza A; Pinti M
Molecules; 2019 Nov; 24(22):. PubMed ID: 31766211
[TBL] [Abstract][Full Text] [Related]
3. Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells.
Wang YY; Yang YX; Zhao R; Pan ST; Zhe H; He ZX; Duan W; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():993-1026. PubMed ID: 25733817
[TBL] [Abstract][Full Text] [Related]
4. CDDO and Its Role in Chronic Diseases.
Mathis BJ; Cui T
Adv Exp Med Biol; 2016; 929():291-314. PubMed ID: 27771930
[TBL] [Abstract][Full Text] [Related]
5. A Point Mutation at C151 of
Gatbonton-Schwager T; Yagishita Y; Joshi T; Wakabayashi N; Srinivasan H; Suzuki T; Yamamoto M; Kensler TW
Mol Pharmacol; 2023 Aug; 104(2):51-61. PubMed ID: 37188495
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice.
Wang YY; Zhang CY; Ma YQ; He ZX; Zhe H; Zhou SF
Drug Des Devel Ther; 2015; 9():3163-78. PubMed ID: 26124639
[TBL] [Abstract][Full Text] [Related]
7. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
[TBL] [Abstract][Full Text] [Related]
8. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection.
Tran TA; McCoy MK; Sporn MB; Tansey MG
J Neuroinflammation; 2008 May; 5():14. PubMed ID: 18474101
[TBL] [Abstract][Full Text] [Related]
9. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.
Walsh J; Jenkins RE; Wong M; Olayanju A; Powell H; Copple I; O'Neill PM; Goldring CE; Kitteringham NR; Park BK
J Proteomics; 2014 Aug; 108(100):171-87. PubMed ID: 24859727
[TBL] [Abstract][Full Text] [Related]
10. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.
Liby KT; Sporn MB
Pharmacol Rev; 2012 Oct; 64(4):972-1003. PubMed ID: 22966038
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure.
Tian C; Gao L; Zhang A; Hackfort BT; Zucker IH
J Pharmacol Exp Ther; 2019 Dec; 371(3):642-651. PubMed ID: 31601682
[TBL] [Abstract][Full Text] [Related]
12. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.
Shishodia S; Sethi G; Konopleva M; Andreeff M; Aggarwal BB
Clin Cancer Res; 2006 Mar; 12(6):1828-38. PubMed ID: 16551868
[TBL] [Abstract][Full Text] [Related]
13. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.
Deeb D; Gao X; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2008; 7(1):31-9. PubMed ID: 18472640
[TBL] [Abstract][Full Text] [Related]
14. Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me).
Yue P; Zhou Z; Khuri FR; Sun SY
Cancer Biol Ther; 2006 May; 5(5):492-7. PubMed ID: 16582599
[TBL] [Abstract][Full Text] [Related]
15. The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity.
Casares L; Moreno R; Ali KX; Higgins M; Dayalan Naidu S; Neill G; Cassin L; Kiib AE; Svenningsen EB; Minassi A; Honda T; Poulsen TB; Wiel C; Sayin VI; Dinkova-Kostova AT; Olagnier D; de la Vega L
Redox Biol; 2022 May; 51():102291. PubMed ID: 35313207
[TBL] [Abstract][Full Text] [Related]
16. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent.
Vannini N; Lorusso G; Cammarota R; Barberis M; Noonan DM; Sporn MB; Albini A
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3139-46. PubMed ID: 18065492
[TBL] [Abstract][Full Text] [Related]
17. In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells.
Kurosaki Y; Imoto A; Kawakami F; Ouchi M; Morita A; Yokoba M; Takenaka T; Ichikawa T; Katagiri M; Nielsen R; Ishii N
Mol Cell Biochem; 2022 Mar; 477(3):689-699. PubMed ID: 34973124
[TBL] [Abstract][Full Text] [Related]
18. CDDO-imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1.
Meng X; Waddington JC; Tailor A; Lister A; Hamlett J; Berry N; Park BK; Sporn MB
J Med Chem; 2020 Sep; 63(17):9965-9976. PubMed ID: 32787104
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.
Thimmulappa RK; Fuchs RJ; Malhotra D; Scollick C; Traore K; Bream JH; Trush MA; Liby KT; Sporn MB; Kensler TW; Biswal S
Antioxid Redox Signal; 2007 Nov; 9(11):1963-70. PubMed ID: 17822364
[TBL] [Abstract][Full Text] [Related]
20. The effect of ex vivo CDDO-Me activation on nuclear factor erythroid 2-related factor 2 pathway in white blood cells from patients with septic shock.
Noel S; Zheng L; Navas-Acien A; Fuchs RJ
Shock; 2014 Nov; 42(5):392-9. PubMed ID: 25105464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
